^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | lapatinib (EGFR inhibitor, HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
Published date:
06/25/2018
Excerpt:
Recommendations...If a patient’s cancer is hormone receptor positive and HER2 positive, clinicians may recommend either:...Endocrine therapy plus trastuzumab or lapatinib (in selected cases; Type: evidence based; Evidence quality: high; Strength of recommendation: moderate).
DOI:
10.1200/JCO.2018.79.2697
Source:
Title:
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
Excerpt:
Recommendations...First line treatment...In selected cases of HER2-positive, HR-positive breast cancer where the patient is not suitable for first-line ChT, ET (e.g. an AI) in combination with a HER2-targeted therapy such as trastuzumab, trastuzumab/pertuzumab, trastuzumab/lapatinib or lapatinib...
DOI:
https://doi.org/10.1016/j.annonc.2021.09.019.
Source:
Excerpt:
HER2 Positive Breast Cancer: Invasive Breast Cancer…SYSTEMIC THERAPY FOR ER - AND/OR PR - POSITIVE RECURRENT OR STAGE IV (M1) DISEASE…HER2-Positive and Postmenopausal Receiving Ovarian Ablation or Suppression...Aromatase Inhibitor ± lapatinib...
Secondary therapy:
Aromatase inhibitor
Source:
Title:
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
Excerpt:
In HR-positive, HER2-positive patients (n = 219), addition of lapatinib to letrozole significantly reduced the risk of disease progression versus letrozole-placebo (hazard ratio [HR]= 0.71; 95% CI, 0.53 to 0.96; P = .019); median PFS was 8.2 v 3.0 months, respectively. Clinical benefit (responsive or stable disease= 6 months) was significantly greater for lapatinib-letrozole versus letrozole-placebo (48% v 29%, respectively; odds ratio [OR] 0.4; 95% CI, 0.2 to 0.8; P= .003).
Secondary therapy:
letrozole
DOI:
10.1200/JCO.2009.23.3734
Source:
Title:
Phase III study of lapatinib (L) plus trastuzumab (T) and aromatase inhibitor (AI) vs T+AI vs L+AI in postmenopausal women (PMW) with HER2+, HR+ metastatic breast cancer (MBC): ALTERNATIVE.
Excerpt:
...benefit of L+T was consistent in key subgroups. mPFS with L vs T was 8.3 vs 5.7 mo (HR = 0.71, 95% CI [0.51, 0.98], P= 0.0361). ORR with L+T, T, and L was 32%, 14%, and 19% respectively….Dual HER2 blockade with L+T+AI showed superior PFS benefit vs T+AI, in pts with HER2+, HR+ MBC.
Secondary therapy:
Aromatase inhibitor
DOI:
10.1200/JCO.2017.35.15_suppl.1004
Trial ID:
Source:
Title:
Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)
Published date:
11/17/2020
Excerpt:
CONTRADICTING EVIDENCE:...participants with early-stage HER2-positive breast cancer (N = 128) were recruited...Participants were randomized to receive trastuzumab (T; N = 34), lapatinib (L; N = 36), or both (TL; N = 58) as HER2-targeted therapy...In the intent-to-treat population, we observed similar pCR rates between T (47%, 95% confidence interval [CI] 30-65%) and TL (52%, 95% CI 38-65%), and a lower pCR rate with L (25%, 95% CI 13-43%)...No significant differences in pCR were observed between arms in the HR− subset; however, in the HR+ subset, L had a significantly lower pCR rate compared to T (p = 0.04) and TL (p = 0.03).
DOI:
10.1038/s41467-020-19494-2
Trial ID:
